Susquehanna Portfolio Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.92M	Sell	23,247 -160,788	-87%	-$23.9M	0.06%	328
2026 Q1	$24.2M	Hold	184,035	–	–	0.36%	74
2025 Q4	$26.1M	Hold	184,035	–	–	0.4%	63
2025 Q3	$25.8M	Hold	184,035	–	–	0.41%	60
2025 Q2	$23.1M	Buy	+184,035	New	+$21.1M	0.51%	45
2024 Q3	–	Sell	-59,455	Closed	-$8.19M	–	448
2024 Q2	$8.19M	Sell	59,455 -55,244	-48%	-$7.58M	0.34%	81
2024 Q1	$15.8M	Hold	114,699	–	–	0.37%	76
2023 Q4	$15.1M	Buy	+114,699	New	+$13.2M	0.27%	109

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Portfolio Strategies's NBIX Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its Neurocrine Biosciences (NBIX) stake by 87% in Q2 2026, selling an estimated $23.9M and leaving 23,247 shares worth $3.92M. The position accounts for 0.06% of the portfolio, ranked #328.

Susquehanna Portfolio Strategies first reported a position in NBIX in Q4 2023 and has held it in 8 quarters since. The position peaked at $26.1M in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Susquehanna Portfolio Strategies held 23,247 shares of Neurocrine Biosciences worth $3.92M as of Q2 2026.
Susquehanna Portfolio Strategies sold 160,788 Neurocrine Biosciences shares in Q2 2026, an estimated $23.9M.
Neurocrine Biosciences made up 0.06% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #328 holding.
Susquehanna Portfolio Strategies first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 8 quarters since.
Susquehanna Portfolio Strategies's Neurocrine Biosciences position peaked at $26.1M in Q4 2025.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.